Revolutionizing breast cancer diagnosis: Ataraxis, a startup that emerged from stealth, has developed an AI-powered diagnostic test called Ataraxis Breast that can more accurately assess the risk severity of breast cancer compared to current methods.
The challenge in cancer treatment: Differentiating between aggressive and low-risk cancers is crucial for determining appropriate treatment strategies.
- Current lab tests can be time-consuming and sometimes limited to specific genetic mutations.
- Inaccurate risk assessment can lead to unnecessary aggressive treatments that may outweigh the actual dangers of the cancer.
Ataraxis Breast: A game-changing solution: The AI-powered diagnostic test developed by Ataraxis aims to provide more precise risk assessments for breast cancer patients.
- The system claims to be up to 30% more accurate than the current standard of care used in many hospitals.
- Ataraxis Breast could potentially help tens of thousands of breast cancer patients avoid unnecessary chemotherapy each year.
Company background and funding: Ataraxis has made significant strides in a short period.
- Founded in 2023 by Jan Witowski (CEO) and Krzysztof Geras (Chief Science Officer).
- The company emerged from stealth with a $4 million seed round co-led by Giant Ventures and Obvious Ventures.
- Yann LeCun, chief AI scientist for Meta, serves as an advisor and contributed to the development of the company’s technical approach.
Technology behind Ataraxis Breast: The diagnostic test utilizes advanced AI techniques to achieve its high accuracy.
- Trained on historic images of tumors from over 4,500 breast cancer patients.
- Combines multiple prediction models and uses the average of each model’s prediction to reduce errors.
- Employs self-supervised learning and other methods to achieve accuracy with less data and compute power.
Validation and future plans: Ataraxis is taking steps to ensure the reliability and expand the applications of its technology.
- The test results were validated using historic early-stage images of 3,500 patients not included in the training data.
- The company plans to conduct more studies to further validate its model.
- Ataraxis aims to develop additional AI-powered insights for breast cancer treatment and expand into other types of cancer.
- The company expects its software to be in use by doctors by early 2025.
Potential impact on healthcare: Ataraxis’ technology has the potential to significantly improve cancer treatment decisions.
- More accurate risk assessment could lead to more tailored and appropriate treatment plans for patients.
- Reduction in unnecessary aggressive treatments could improve patient quality of life and reduce healthcare costs.
- The company’s approach could pave the way for similar AI-powered diagnostic tools in other areas of medicine.
Analyzing deeper: While Ataraxis’ technology shows promise, it’s important to note that the study results have not yet been peer-reviewed. As the company moves forward with further validation and clinical implementation, it will be crucial to monitor real-world performance and any potential limitations or biases in the AI model. Additionally, the integration of such AI-powered tools into clinical practice may require changes in healthcare infrastructure and additional training for medical professionals to ensure optimal use and interpretation of the results.
Recent Stories
DOE fusion roadmap targets 2030s commercial deployment as AI drives $9B investment
The Department of Energy has released a new roadmap targeting commercial-scale fusion power deployment by the mid-2030s, though the plan lacks specific funding commitments and relies on scientific breakthroughs that have eluded researchers for decades. The strategy emphasizes public-private partnerships and positions AI as both a research tool and motivation for developing fusion energy to meet data centers' growing electricity demands. The big picture: The DOE's roadmap aims to "deliver the public infrastructure that supports the fusion private sector scale up in the 2030s," but acknowledges it cannot commit to specific funding levels and remains subject to Congressional appropriations. Why...
Oct 17, 2025Tying it all together: Credo’s purple cables power the $4B AI data center boom
Credo, a Silicon Valley semiconductor company specializing in data center cables and chips, has seen its stock price more than double this year to $143.61, following a 245% surge in 2024. The company's signature purple cables, which cost between $300-$500 each, have become essential infrastructure for AI data centers, positioning Credo to capitalize on the trillion-dollar AI infrastructure expansion as hyperscalers like Amazon, Microsoft, and Elon Musk's xAI rapidly build out massive computing facilities. What you should know: Credo's active electrical cables (AECs) are becoming indispensable for connecting the massive GPU clusters required for AI training and inference. The company...
Oct 17, 2025Vatican launches Latin American AI network for human development
The Vatican hosted a two-day conference bringing together 50 global experts to explore how artificial intelligence can advance peace, social justice, and human development. The event launched the Latin American AI Network for Integral Human Development and established principles for ethical AI governance that prioritize human dignity over technological advancement. What you should know: The Pontifical Academy of Social Sciences, the Vatican's research body for social issues, organized the "Digital Rerum Novarum" conference on October 16-17, combining academic research with practical AI applications. Participants included leading experts from MIT, Microsoft, Columbia University, the UN, and major European institutions. The conference...